share_log

UBS Initiates Coverage On 10x Genomics With Neutral Rating, Announces Price Target of $50

UBS Initiates Coverage On 10x Genomics With Neutral Rating, Announces Price Target of $50

瑞銀開始覆蓋 10 倍基因組學的中性評級,宣布目標價格為 50 美元
Benzinga Real-time News ·  2023/02/02 08:44

UBS analyst John Sourbeer initiates coverage on 10x Genomics (NASDAQ:TXG) with a Neutral rating and announces Price Target of $50.

瑞銀分析師John Sourmer對10倍基因組(納斯達克:TXG)發起報道,評級為中性,並宣佈目標價為50美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論